Microbes in Your Mouth May Impact Your Risk of Cognitive Decline
The bacteria living inside your mouth could be influencing more than just the health of your gums and teeth. Your brain might also be impacted by these oral colonizers.
In a study of 55 participants with mild cognitive impairment (MCI), those who hosted a relatively high abundance of bacteria from the genus Neisseria in their mouths had better working memory, executive function, and visual attention.
Even among 60 people without cognitive decline, when Neisseria dominated the oral microbiome, working memory scores improved.
The current study, led by researchers at the University of Exeter in the UK, suggests that by promoting certain bacteria in the mouth we could potentially delay cognitive decline. This could be achieved with probiotics or prebiotics that can boost and feed certain microbial communities in the oral cavity within just weeks.
The findings align with other recent studies, which suggest the cause of dementia may be coming from inside the mouth.
In recent years, for instance, poor oral health has emerged as a major risk factor for cognitive decline. Scientists have even found some bacteria linked to gum disease in the brains of those who have died from Alzheimer's.
Still, not all microbes in the mouth are necessarily harmful to the brain; some could be protective, too. Similar to bacteria in the gut, a nicely balanced microbiome is key.
The Neisseria genus includes more than 20 species of bacteria, many of which typically live in the nose and mouth quite peacefully and may even confer health benefits.
Recently, studies have found Neisseria bacteria can lower a person's systemic blood pressure by helping to convert nitrate-rich foods (usually vegetables) to nitric oxide.
Nitric oxide is a key signaling molecule in the body, which protects against gum disease and helps control and regulate blood pressure, as well as our cardiovascular response to exercise. It could also help keep the brain healthy.
Based on recent evidence, some neuroscientists suspect nitric oxide may protect the central nervous system by boosting neural plasticity and improving the efficiency and power of neural messages. The signaling molecule may even reduce neural inflammation – a central mechanism of Alzheimer's.
Intriguingly, people who are genetically predisposed to Alzheimer's tend to have trouble naturally producing nitric oxide.
In the current study, molecular biologist Joanna L'Heureux and her colleagues found that of 33 participants with MCI who were genetically predisposed to Alzheimer's, many had oral microbiomes dominated by the Prevotella genus and not the Neisseria genus.
One species of Prevotella in particular, P. intermedia, was a predictor for an elevated genetic risk for dementia. This suggests it could be used as an early marker of disease risk.
In the study, when the Prevotella genus reigned, there was less nitrate available in the mouth to convert to nitric oxide, probably because Prevotella uses the nitrate for other means.
Thus, by promoting Neisseria and eradicating Prevotella in the mouth, the authors of the study think they could potentially influence nitric oxide availability, thereby influencing the health of the brain.
Nitrate-rich diets, like the Mediterranean diet, are linked to improved brain health, but further research is needed to understand the link between what we put in our mouths, our oral microbiome, and the major signaling molecules produced by those microbes.
A 2021 study in healthy older people, for instance, found a correlation between oral microbiomes dominated by Neisseria (and a co-occurring genus, called Haemophilus) and sustained attention, even when the amount of dietary nitrate changed.
Other research has linked higher rates of Neisseria to younger age, lower body mass index, fewer teeth with damage, and not smoking.
"Collectively, these results indicate that a high relative abundance of bacteria belonging in the Neisseria–Haemophilus module is associated with better cognitive outcomes in individuals with MCI as well as in healthy older people," conclude L'Heureux and her team.
The study was published in PNAS Nexus.
Tuberculosis Outbreak in Kansas Is Among Largest on Record in US
Scientists Confirm a New Strain of Bird Flu Has Emerged in The US
Exercise Doesn't Burn as Many Calories as You Think, Experts Say
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")
Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the human gene called Klotho. NEW YORK, June 9, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company announced the findings of pre-clinical studies indicating the potential of elevating Klotho gene expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span. Pioneering discoveries by Professor Makoto Kuro-O in 1997 showed that Klotho concentrations in the blood were directly associated with lifespan of mammals – the lower the Klotho blood levels the shorter the lifespan. Kuro-O's laboratory then published the first evidence that genetic over expression of the full-length form of Klotho in mice, increased in lifespan of mice of up to 30%-40% longer compared to the normal mouse lifespan. Since then, the Klotho protein has gained much attention because of its ability to influence key biological pathways involved in metabolism, inflammation and tissue repair, which are closely linked to the aging process. A series of experiments led by Joan Roig-Soriano and colleagues, published in the February 2025 edition of Molecular Therapy, highlights the promising role of the naturally occurring secreted form of the Klotho protein ("s-KL") and its effects on healthy aging mice and mice with a rapidly aging phenotype. Key observations were that, while aging is a major risk factor for many pathologies, including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis, the secreted protein s-KL has emerged as a potentially promising therapeutic anti-aging molecule due to its many biological effects involving multiple pathways related to cell injury, stress, and inflammation. The s-KL was administered using an adeno-associated virus serotype 9 delivery vector (AAV9) that expressed the secreted KL protein isoform and efficiently increased the concentration of s-KL in serum, resulting in a 20% increase in lifespan. Dr. Joseph Sinkule, the CEO of Klotho Neurosciences (KLTO) commented that "KLTO has secured an exclusive worldwide license for s-Kl from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Spain. As a result, we have the exclusive use of patents issued in the USA, Europe, and China covering a secreted splice variant of mammalian Klotho referred to as s-KL, as a treatment for neurodegenerative and age -related disorders. Professor Makoto Kuro-O is also a scientific advisor to KLTO. This recently published paper provides further credence to our development of s-KL as a treatment to reduce age-associated degeneration where, as a company, KLTO has a particular focus on neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span". About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, contact:Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFOjeff@ Website: Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc.
Yahoo
4 hours ago
- Yahoo
Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery's Substack. In this article, we will summarize the bulls' thesis on LLY. Eli Lilly and Company (LLY)'s share was trading at $765.68 as of 5th June. LLY's trailing and forward P/E were 62.30 and 35.09 respectively according to Yahoo Finance. A picture of a pharma technician preparing an IV injection of a biopharmaceutical product. Eli Lilly is no longer just a pharmaceutical giant—it's becoming a platform company that's reshaping the very structure of global healthcare. At the heart of this transformation is tirzepatide, a dual-action molecule marketed under separate brands for diabetes and obesity. This single drug now accounts for over a quarter of Lilly's total revenue, with the diabetes version generating $11.5 billion (up 330% YoY) and the obesity variant reaching $2.3 billion in its first year—a historic ramp-up. These are not just growth numbers; they're margin-rich results, with 85 %+ gross margins and minimal marketing spend due to entrenched trust among endocrinologists. Crucially, tirzepatide is protected by a fortress of patents through 2036 and beyond, giving Lilly a durable edge in two massive markets. Unlike peers, Lilly owns its injectable manufacturing end-to-end, having invested over $5.5 billion in internal capacity, giving it unmatched agility and control while rivals struggle with supply constraints. Its sales force and deep prescriber relationships, built over decades, have only grown more powerful thanks to a new direct-to-consumer platform that streamlines initiation and adherence. Meanwhile, the company is reinvesting aggressively, with $11 billion (24% of revenue) spent on focused R&D spanning Alzheimer's, oncology, and rare diseases. Its pipeline—anchored in metabolic, neurodegenerative, and immune disorders—builds on existing strengths, accelerating commercialization. Competition exists, but Lilly's molecule consistently outperforms, and its infrastructure outscales. With two-thirds of sales still U.S.-based, global expansion represents the next lever. In sum, Lilly's model—a convergence of science, scale, and system—positions it as more than a pharma company. It's a precision biology platform with extraordinary strategic depth and long-term compounding potential. Previously, we covered a bullish thesis on Eli Lilly (LLY) by Kontra on Substack in May 2025, which aligns with Business Model Mastery's analysis, emphasizing the company's leadership in obesity and diabetes care. Both highlight tirzepatide's explosive growth, margin strength, and Lilly's massive investment in capacity and R&D. Kontra focuses more on near-term financial results, pipeline expansion, and regulatory catalysts, while Business Model Mastery frames Lilly as a precision biology platform with structural advantages—like end-to-end manufacturing and patent longevity—that support durable outperformance. Together, they reinforce Lilly's status as a long-term compounder with deep moats and global runway. Eli Lilly and Company (LLY) is on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 119 hedge fund portfolios held LLY at the end of the first quarter which was 115 in the previous quarter. While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
4 hours ago
- Yahoo
Big Data Can Make America Healthier. How to Do It Right
Credit - Ezra Bailey—Getty Images Big data can help make Americans healthier, and the Trump Administration has stated—in its recently released Make America Healthy Again report and elsewhere—that building a national big-data platform is one of its primary goals. As scientists who use large data sets to study health, we're excited about its potential and the willingness of the federal government to invest in it, particularly since big data has been underutilized in the U.S. compared with other developed countries—and since the number of ways it can be used grows nearly daily. It's a huge opportunity. But there are lots of concerns when assembling sensitive health data and combining it with other sensitive data, like credit scores, tax records, employment, educational records, and more. Some of those concerns with the Administration's plans have already surfaced. The Administration's first goal of assembling big data to studying autism has left some worried that if used inappropriately, such data could lead to harm, rather than help, for those with autism. Others worry that big data could be used to perform and justify shoddy research that supports predetermined conclusions without adhering to rigorous scientific methods—a concern reinforced by the discovery that the Make America Healthy Again report cited non-existent sources to support its claims. So how can we reap the benefits of big data while minimizing its risks? Here are some guiding principles: The health care system already possesses health data on millions of Americans. Medical records are now almost always digitized, permitting doctors' notes, medical imaging, laboratory tests, insurance claims, and more to be linked (in theory) across doctors' offices, hospitals, nursing homes, and any other place people receive care. However, data collected about a patient in one setting often doesn't get connected to data from other settings—making it hard for researchers to get a full picture of what, exactly, is happening to each of us within the larger health care system. Read More: Gun Injuries of All Kinds Go Up During Hunting Season The federal government also has data on us that can be connected to health care data to answer important questions. For example, comprehensive and detailed data on Americans' occupations linked with health, insurance, and other data could help shed more light on relationships between our work and our health—helping to better answer curious questions like why taxi drivers are less likely to die from Alzheimer's disease or why female physicians don't outlive their male colleagues. The first step of making big data more helpful is to simply link the data—which, while possible, is difficult to accomplish without centralized effort. Once linkages have been made, data can be anonymized so that those studying sensitive questions aren't privy to confidential information about specific individuals. In addition to governmental data, many other sources of data can provide insights into our health. For example, smartwatches not only have data on how our hearts are beating (e.g., they can identify abnormal heart rhythms like atrial fibrillation), but they can also identify subtle changes in mobility that might be predictive of early neuromuscular diseases like Parkinson's disease. Meanwhile, grocery stores have data on the foods we eat, and with increasing interest in how diet affects our lives, these data could be linked to detailed measures of health. Read More: Could the Shingles Vaccine Help Prevent Dementia? Similarly, social-media platforms possess data that can offer insights into changes in our mental health, and through large-scale analysis of online photos could even identify, in real time, early visible markers of disease. These are moonshots, of course, and whether we want to use data in this way is an open question. But the potential to improve health could be large. Creating a way for scientists to link outside data to existing government and health data—while responsibly maintaining individual anonymity after the linkage—could open many novel research opportunities. Keeping all of these data sources organized, secure, and accessible to scientists is a tall order. Researchers who use big data often dedicate substantial resources to finding the data they need, organizing it, and ensuring its accuracy; the better the database is maintained, the easier it is for researchers to actually perform their analyses. The secure online platform where Medicare and other government health care data are currently accessed has been described by researchers as 'tedious and prone to system errors' and in need of major improvements. Meanwhile, security concerns have led the government to stop letting researchers store the data on their own secure servers, the easiest and most cost-effective way to actually work with the data. Access to Medicare data by researchers has become prohibitively expensive, costing about $30,000 a year or more for a single user to work on one project using the online platform. Read More: Why We Can't Rely on Science Alone to Make Public Health Decisions Proposals to drastically cut medical research funding have been reported, and if passed, these research funding cuts will come at the cost of discoveries to improve health that will never be made. High-quality research of any kind requires investment, whether it's in a biology lab under a microscope or working with data on powerful computers. A new data platform is only as valuable as researchers' ability to access it in a functional and cost-effective way. Any roadmap to designing a national data platform that links together health care and other sensitive data must consider the many valid concerns about collecting data in the U.S., including privacy concerns and how data will be used. The Pew Research Center finds that large majorities of Americans say they are concerned about how the government uses data collected about them (71%), while also admitting that they have little to no understanding of what the government even does with such data (77%). Here are some strategies—in addition to many of the cybersecurity and privacy safeguards already in place—to both protect the data and help earn the public trust: Mistrust and unease with government data collection is readily traceable to historical abuse of Americans' data (as well as recent allegations of improper access), so it's not surprising that many are wary of the Trump Administration's plans. Ensuring data cannot be weaponized by the government against individuals is perhaps the single biggest barrier to creating a useful database, but it can be done. Those currently using federal health care data must already undergo training and comply with very high data-security standards. Misuse of the data—such as even attempting to figure out the identity of an anonymous individual in the data—or failure to protect patient privacy can lead to criminal penalties. A platform of sensitive data without well-delineated restrictions on who can use it and what they can use it for is a recipe for problems. Other ongoing efforts by the Administration to compile data under the vague goal of 'increasing government efficiency' have been met with pushback and lawsuits from organizations concerned about data being used against members of the public. Current use of federal health data also requires researchers to provide the government detailed plans to justify the use of specific data. This allows the government to ensure that no more data than is needed to answer the specific question is provided to researchers. Read More: Why Do Taxi Drivers Have a Lower Risk of Alzheimer's? Researchers must also obtain ethical approval from an Institutional Review Board prior to accessing and analyzing data, a second checkpoint. These boards, which exist in light of egregious failures of medical research ethics in the 20th century, help ensure that analyses are designed to minimize risk to patients—even if it is only their data, and not their bodies, at risk. Transparency into who is using this sensitive data and what exactly they are doing with it can engender trust between researchers and the American public. Just like researchers already do for clinical trials, those accessing the data platform should specify their plans in advance, and those plans should be easily and publicly available. Transparency around which data were accessed and what computer code was used to analyze it not only promotes trust, but such data- and code-sharing practices among researchers make it easier to appraise the quality of the work, identify mistakes, and root out misconduct. We can only assume that Americans' unease with governmental data use stems from knowledge that, as with all powerful tools, linked data has the potential to be used in potentially harmful ways. But when in the hands of qualified scientists using rigorous scientific methods and privacy safeguards, a robust real-world data platform like this could lead to new discoveries about how all of us can lead healthier lives. Contact us at letters@
